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Abstract
Context: Insulin resistance in polycystic ovary syndrome (PCOS) may increase the risk 
of reactive hypoglycaemia (RH) and decrease glucagon-like peptide-1 (GLP-1) secretion. 
The possible effects of treatment with oral contraceptives (OCP) and/or metformin 
on GLP-1 secretion and risk of RH in PCOS is undetermined.
Setting: Outpatient clinic.
Patients and interventions: Randomized, controlled clinical trial. Ninety women with 
PCOS were randomized to 12-month treatment with OCP (150 mg desogestrel + 30 mg 
ethinylestradiol), metformin (2 g/day) or metformin + OCP. Five-hour oral glucose 
tolerance tests (5-h OGTT) measuring fasting and area under the curve (AUC) for GLP-1, 
glucose, insulin and C-peptide were performed before and after the intervention period. 
Sixty-five women completed the study and 34 weight-matched healthy women were 
included as controls.
Main outcome measures: Changes in GLP-1, glucose, insulin and C-peptide during 
5-h OGTT.
Results: Fasting GLP-1 levels increased during metformin + OCP vs OCP treatment, 
whereas AUC GLP-1 levels were unchanged during medical treatment. The prevalence 
of reactive hypoglycemia increased from 9/65 to 14/65 after intervention (P < 0.01) and 
was more common after treatment with metformin + OCP (increase from 3/23 to 6/23, 
P = 0.01). Reactive hypoglycaemia was associated with higher insulin and C-peptide 
levels during 5-h OGTT, but was unassociated with BMI and AUC GLP-1. GLP-1 levels 
were comparable in PCOS vs controls. AUC GLP-1 levels were significantly lower in 
obese vs lean patients and were inversely associated with BMI.
Conclusions: AUC GLP-1 levels were unchanged during treatment. Increased risk of 
hypoglycemia during metformin + OCP could be associated with increased insulin 
secretion.
Introduction
Polycystic ovary syndrome (PCOS) is characterized by 
oligo/anovulation, hyperandrogenaemia and polycystic 
ovaries (1, 2). Hyperinsulinaemia as a consequence of 
insulin resistance is present in most patients with PCOS 
(1). Incretin hormones are released after meal ingestion 
and account for up to 70% of postprandial insulin 
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secretion (3). Glucagon-like peptide-1 (GLP-1) and gastric 
inhibitory polypeptide are the most important incretin 
hormones. GLP-1 secretion is impaired in insulin resistant 
states such as obesity and type 2 diabetes (3), whereas 
results in patients with PCOS are conflicting (4, 5, 6).
Reactive hypoglycaemia (RH) is defined as a drop 
in blood glucose levels 1½–5 h after food consumption 
without indication of hypoglycaemia due to other causes 
(7). RH was prevalent in obese and lean patients with 
PCOS (8, 9) and was associated with insulin resistance 
and hyperinsulinaemia especially in obese patients (9). 
RH may contribute to the development of obesity by 
increasing appetite-evoking hormones such as leptin (10). 
Increased GLP-1 activity contributed to hypoglycemia 
after gastric bypass (11), but possible associations between 
RH and GLP-1 levels in PCOS have not been investigated.
Treatment modalities in PCOS aim at decreasing 
hyperandrogenism and improving insulin sensitivity 
along with weight loss (12, 13). Oral contraceptive 
treatment (OCP) regulates menstrual cycles and SHBG 
levels are increased, leading to decreased levels of free 
testosterone (14). OCP may increase body weight (15) 
and insulin resistance (14, 16), which could be associated 
with decreased GLP-1 levels. In contrast, animal studies 
suggested that estradiol and progesterone treatment could 
increase the effect and secretion of GLP-1 (4, 17). In one 
recent uncontrolled study, GLP-1 levels were unchanged 
during a meal tolerance test after 3  months of OCP 
treatment (ethinyl estradiol 30 µg/drospirenone 3 mg) in 
14 lean patients with PCOS (4), but we are not aware of 
data in obese patients with PCOS. Increased insulin levels 
during OCP could be associated with increased risk of RH 
in PCOS, but no study tested this hypothesis.
Treatment with metformin improved insulin 
sensitivity and ovulatory function in PCOS (14), whereas 
androgen levels were only slightly decreased (14, 18). We 
recently reported a significant weight loss of 3.0 kg during 
12-month metformin treatment (15). Decreased insulin 
levels during metformin treatment could be associated 
with decreased risk of RH and hence decreased appetite (9). 
Ghrelin levels decreased (19) and GLP-1 levels increased 
(6) after treatment with metformin in two uncontrolled 
studies in PCOS, which could have opposite effects on the 
risk of RH, but we are not aware of controlled studies that 
investigated the effect of metformin on GLP-1 levels or 
risk of RH in PCOS.
The primary aim of the present study was to perform 
5-h oral glucose tolerance tests (5-h OGTT) and evaluate the 
possible effects of treatment with OCP and/or metformin 
on GLP-1 levels and risk of RH in patients with PCOS. 
Measures of GLP-1 secretion were furthermore compared 
in women with PCOS and weight-matched controls.
Methods
The methods of the present intervention study have 
been described recently in a paper regarding the effects of 
OCP and/or metformin treatment on body composition 
measures (15). Baseline data in patients and controls were 
reported in a paper on RH in PCOS (9). Two patients were 
excluded in (9) due to incomplete data, but were included 
in the present data as both patients completed study 
intervention.
Patients
Ninety white women aged 18–39 years with PCOS were 
included. The patients fulfilled the Rotterdam criteria 
for PCOS with minimum two of three of the following 
criteria: (1) Irregular periods during more than a year with 
a cycle length >35 days; (2) total or free testosterone levels 
above reference interval (upper limits: total testosterone 
>1.8 nmol/L, free testosterone >0.035 nmol/L) and/or 
hirsutism and (3) transvaginal ultrasound with polycystic 
ovaries. Patients paused OCP for at least three months 
and metformin for at least one month before evaluation 
and were not treated with medicine known to affect 
hormonal or metabolic parameters. Patients randomized 
to metformin treatment alone consented to use barrier 
contraception during the study period or had an 
intrauterine device implanted.
Exclusion criteria
Patients with contraindications for OCP (obesity with 
BMI ≥35 kg/m2, previous or family history of thrombosis 
or breast cancer, coagulation defects and heavy smoking) 
and patients with diabetes (fasting plasma glucose 
≥7.0 mmol/L and/or HbA1c ≥48 mmol/mol), elevated 
liver enzymes, self-reported renal dysfunction, congestive 
heart disease, depression and eating disorders were 
excluded. Routine measurements included prolactin, total 
and free testosterone, TSH, 17-hydroxyprogesterone, liver 
enzymes, HbA1c, plasma glucose and electrolytes.
Power calculation
Previous short-term studies on metformin and OCP 
treatment in PCOS using area under the curve (AUC) 
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for insulin during 2-h OGTT as the primary end point 
included a minimum of 15 patients in each group (20, 21). 
There was no published data on GLP-1 levels in PCOS by 
the time of study planning. It was therefore impossible to 
perform a power calculation on the effect of OCP and/or 
metformin treatment on GLP-1 levels and 30 patients 
were arbitrarily included in each treatment arm.
Controls
Thirty-four healthy white women matched to the group of 
women with PCOS regarding BMI and age were included. 
All controls had regular menstrual cycles and did not have 
hirsutism. Controls had paused OCP for at least three 
months prior to evaluation.
The study was approved by the local ethics committee 
(Region of Southern Denmark, study ID S-20070020) and 
by the Danish Medicines Agency, and all subjects gave 
written informed consent. The trial was registered at 
www.clinicaltrials.gov, registration number NCT00451568 
(intervention study) and NCT01995773 (controls).
Study protocol
Patients were randomized to 12-month treatment with 
metformin (1 + 1 g/day), OCP (150 mg desogestrel + 30 mg 
ethinylestradiol) or combined treatment, metformin + OCP. 
Before the intervention, patients underwent physical 
examination including transvaginal ultrasound, fasting 
blood samples and 5-h OGTT. After 12-month medical 
treatment, the patients were admitted for repeated 
examinations similar to the initial evaluation program. 
Examinations were performed on a random cycle day. 
Safety tests were performed after 6 and 12  months and 
included weight, blood pressure, HbA1c, liver enzymes, 
electrolytes and white blood cell count. Pregnancy tests 
were performed by the participants each month.
Clinical examination
Clinical examination included Ferriman–Gallwey score, 
blood pressure, waist-to-hip ratio, height and weight.
Fasting blood samples and 5-h OGTT
A 5-h OGTT was performed after overnight fasting. 
GLP-1, capillary blood glucose (BG), insulin and 
C-peptide were measured at baseline (fasting) and at 30, 
60, 90, 120, 180, 240 and 300 min after oral ingestion of a 
glucose load containing the equivalent of 75 g anhydrous 
glucose dissolved in water. Homeostasis model assessment 
(HOMA-r) was calculated as fasting insulin×fasting 
BG/22.5. RH was defined as BG <3.3 mmol/L occurring 
between 120 and 300 min during the 5-h OGTT. Two and 
5 h AUC for glucose, insulin and C-peptide during 5-h 
OGTT was calculated applying the trapezium rule.
Assays
We measured total GLP-1 levels, i.e. the sum of intact 
GLP-1 and the metabolite generated by dipeptidyl-
peptidase 4-mediated degradation, which is the relevant 
parameter for evaluation of secretion and potential actions 
of GLP-1 (22). GLP-1 concentrations were measured by 
radioimmunoassay after extraction of plasma with 70% 
ethanol (vol/vol, final concentration). The carboxy-
terminal GLP-1 immunoreactivity was determined using 
antiserum 89,390, which has an absolute requirement for 
the intact amidated carboxy-terminus of GLP-1 7-36-amide 
and cross-reacts less than 0.01% with carboxy-terminally 
truncated fragments and at least 89% with GLP-1 9-36-
amide, the primary metabolite of dipeptidyl-peptidase 
4-mediated degradation. The sum of the two components 
(total GLP-1 concentration) reflects the rate of secretion 
of the L-cell. The sensitivity was below 1 pmol/L and the 
intra-assay coefficient of variation (CV) was below 5% 
(23). All samples were measured in the same period, using 
identical reagents and quality controls.
Total testosterone was analyzed using an in-house 
method based on the extraction of steroids from serum 
by ether, separation of extracted steroids by liquid 
chromatography and quantification by radioimmunoassay 
as previously described (24). In this method, testosterone, 
dihydrotestosterone and androstendione are extracted 
before applying radioimmunoassay and overestimation 
of testosterone levels is hereby avoided. The results of 
this method correlate closely with the determination of 
testosterone levels using mass spectrometry (25). SHBG 
was analyzed by time-resolved immunoassay using an 
AutoDELFIA commercial kit (Wallac Oy, Turku, Finland). 
Free Testosterone Index (FTI) was calculated from 
measurements of total testosterone and SHBG. The intra-
assay CV was 8.2 for total testosterone and 5.2% for SHBG. 
The inter-assay CV was 13.8% for total testosterone and 
7.5% for SHBG.
Serum levels of insulin and C-peptide were analyzed 
by time-resolved fluoroimmunoassay using commercial 
AutoDELFIA, kits (PerkinElmer Life Sciences). The intra-
assay CV was 1.1–5.0% for C-peptide 1.1–5.0% and 
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2.1–3.7% for insulin. The inter-assay CV was 1.1–3.4% for 
C-peptide and 3.4–4.0% for insulin.
Ethics
The study was approved by the local ethics committee 
(Region of Southern Denmark, study ID S-20070020) and 
by the Danish Medicines Agency and all subjects gave 
written informed consent.
Statistical analysis
Variables are presented as medians and quartiles. Pre-
treatment differences between included patients in the 
three treatment arms were tested using the Kruskall–
Wallis test followed by the Mann–Whitney U test. The 
Mann–Whitney test was used to compare the differences 
between patients and controls and between subgroups of 
patients with PCOS.
Spearman bivariate associations were performed to 
evaluate associations between AUC GLP-1 and BMI.
Basal differences between patients randomized to 
the three different interventions and drop-out during 
follow-up were taken into account by comparing delta (Δ) 
values of hormonal and metabolic variables between the 
three intervention groups using the Kruskall–Wallis test 
followed by the Mann–Whitney U test. Delta values were 
calculated as post-treatment level minus pre-treatment 
level of each analyzed variable.
All statistics were performed using SPSS 17.0 (SPSS). 
P values <0.05 were considered significant.
Results
Of the 90 enrolled patients, 65 patients (72%) completed 
the whole study period (Fig. 1), previously presented in 
(15). Patients randomized to the three treatment groups 
were comparable regarding all clinical and biochemical 
characteristics (Table 1).
Effects of medical intervention
Metformin vs OCP Changes in GLP-1 (fasting, AUC 
and 5-h OGTT) were comparable during metformin and 
OCP treatment, whereas treatment with metformin was 
followed by decreased weight, insulin (time points 120, 
180, 240 and 300 min during 5-h OGTT) and C-peptide 
Figure 1
Flow chart of included and excluded subjects and 
study design.
PCOS 
n= 90 (36 NW+54 OW)
Metformin
n= 30 (15 +15)
Oral contraceptive(OCP)
n= 30 (11+19)
Metformin+OCP
n= 30 (10+20)
Metformin
n= 19 (8+11)
OCP
n= 23 (8+15)
Metformin+OCP
n= 23 (6+17)
Drop outs = 11 (7+4)
Pregnant, n=1
Wants OC, n=2
Depression, n=1
Nausea, n=1
Regrets, n=4
Lost to follow up, n=2
Drop outs= 7 (3+4)
Wants pregnancy, n=2
Side effects, n=3
Lost to follow up, n=2
Drop outs = 7 (4+3)
Nausea, n=3
Regrets, n=2
Lost to follow up, n=2
Data presented as number of participants (number of normal weight + overweight patients) 
OCP= oral contraceptive treatment 
NW: normal weight, BMI < 25 kg/m2
OW: overweight, BMI ≥ 25 kg/m2
Drop outs NW= 14/36= 38.8%, drop outs OW= 11/54= 20.3%, p=0.06. 
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(fasting and time points 180, 240 and 300 min during 5-h 
OGTT and 5-h AUC) compared to OCP (Fig. 2 and Table 2).
Metformin + OCP vs OCP Treatment with metfor-
min + OCP was associated with increased fasting GLP-1, 
whereas changes in AUC GLP-1 were comparable. Weight, 
insulin (fasting and time point 240 min during 5-h OGTT) 
and fasting C-peptide decreased during metformin + OCP 
compared to OCP.
Metformin vs metformin + OCP Changes in GLP-1 
(fasting, AUC and during 5-h OGTT) were comparable 
during metformin vs metformin + OCP. Metformin treat-
ment was followed by decreased weight, BMI, insulin 
(time points 180 and 300 min during 5-h OGTT) and 
C-peptide (fasting and at time points 180 and 240 min 
during 5-h OGTT) compared to changes during treatment 
with metformin + OCP.
RH during medical intervention
The prevalence of RH increased significantly from 9/65 to 
14/65 after study intervention (P = 0.01). The prevalence 
of RH during metformin + OCP increased significantly 
(from 3/23 to 6/23, P = 0.01) and was unchanged during 
metformin (from 1/19 to 3/19, P = 0.16) and during OCP 
(before and after 5/23).
Patients with RH after study intervention were 
characterized by higher 2-h AUC insulin (61.3 (39.6; 80.4) 
vs 40.0 (28.3; 60.9) × 103 pmol/L × h) and 5-h AUC insulin 
(85.4 (61.4; 106.7) vs 59.3 (42.6; 97.8) × 103 pmol/L × h) 
at 12  months compared to patients without RH, 
whereas fasting GLP-1 levels (9.0 (7.0; 11.0) vs 11.3 (9.3; 
13.3) mmol/L) were lower. 2-h and 5-h AUC GLP-1, age 
and BMI were comparable in patients with and without 
RH (data not shown). In patients with BMI ≥25 kg/m2, the 
prevalence of RH increased from 7/43 to 10/43 (P = 0.04) 
and in normal-weight patients, the prevalence of RH 
increased from 2/22 to 4/22 (P = 0.03) during medical 
intervention.
Patients with PCOS vs controls and obese vs lean 
patients with PCOS
GLP-1 GLP-1 levels (fasting and during 5 h OGTT) were 
comparable in patients vs controls (Table  3), in lean 
patients vs lean controls, and in obese patients vs obese 
controls (data not shown). GLP-1 levels were higher in 
lean vs obese patients (Fig. 3 and Table 4) and in lean vs 
obese controls (data not shown). Two-hour and 5-h AUC 
GLP-1 levels were inversely associated with BMI in patients 
with PCOS (r = −0.31 and r = −0.34, respectively, P < 0.004), 
but these associations were non-significant in controls 
(Tables 3 and 4).
Table 1 Baseline clinical and biochemical data in patients with PCOS completing medical intervention (n = 65).
 Metformin (n = 19) OCP (n = 23) Metformin + OCP (n = 23)
Age (years) 31 (24; 33) 28 (24; 32) 30 (24; 31)
Weight (kg) 73.6 (69.2; 83.5) 86.0 (62.1; 88.8) 80.2 (70.5; 86.0)
BMI (kg/m2) 25.9 (24.1; 29.6) 28.0 (22.9; 31.8) 27.6 (24.3; 31.2)
T-testosterone (nmol/L) 1.96 (1.30; 2.88) 1.65 (1.39; 2.69) 1.60 (1.26; 2.32)
SHBG (nmol/L) 44 (32; 62) 52 (36; 82) 47 (32; 72)
FTI 0.04 (0.03; 0.05) 0.03 (0.02; 0.05) 0.03 (0.02; 0.04)
Fasting    
 GLP-1 (mmol/L) 8.5 (6.9; 10.5) 9.5 (7.5; 11.0) 8.8 (7.0; 10.6)
 Insulin (pmol/L) 51 (34; 71) 49 (33; 75) 47 (29; 93)
 C-peptide (pmol/L) 611 (467; 906) 564 (458; 821) 563 (492; 890)
 HOMA (mmol/L nmol/L) 11.7 (7.0; 19.8) 11.6 (7.8; 17.0) 10.9 (6.9; 23.5)
OGTT    
 2 h AUC GLP-1 (102 mmol/L × h) 19.8 (16.7; 23.8) 19.7 (14.6; 22.7) 17.5 (15.6; 20.3)
 5 h AUC GLP-1 (102 mmol/L × h) 38.4 (32.5; 47.4) 39.5 (30.9; 43.9) 37.6 (31.7; 41.9)
 2 h AUC BG (102 mmol/L × h) 9.2 (8.3; 10.0) 8.5 (8.0; 9.7) 8.7 (8.3; 9.9)
 5 h AUC BG (102 mmol/L × h) 17.8 (16.4; 19.5) 17.0 (16.3; 18.7) 18.5 (16.6; 19.3)
 2 h AUC insulin (103 pmol/L × h) 39.8 (30.1; 54.2) 44.7 (30.0; 66.8) 39.8 (27.0; 73.8)
 5 h AUC insulin (103 pmol/L × h) 51.5 (41.3; 77.4) 56.9 (42.8; 92.8) 68.0 (41.3; 115.1)
 2 h AUC C-peptide (104 pmol/L × h) 25.8 (22.0; 34.3) 28.3 (22.2; 33.7) 26.4 (21.7; 35.4)
 5 h AUC C-peptide (104 pmol/L × h) 46.0 (37.1; 66.6) 48.0 (39.7; 61.4) 52.8 (39.4; 61.8)
Data presented as median (25; 75 quartiles). No significant differences between groups (Kruskall–Wallis test).
FG total, total Ferriman–Gallwey score; FTI, free testosterone index; OCP, oral contraceptive treatment.
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RH RH was found in 15/90 (16.7%) patients and 0 
controls (9). Patients with RH had significantly higher 
fasting GLP-1 8.0 (6.0; 10.0) mmol/L vs patients without 
RH 7.0 (9.5; 11.0) mmol/L, P < 0.04. GLP-1 levels during 
5-h OGTT were comparable in patients with RH vs patients 
without RH. As recently presented, the presence of RH was 
independent of BMI (9), data not shown.
Insulin and C-peptide Women with PCOS had sig-
nificantly higher levels of insulin (fasting, 2- and 5-h 
AUC) and C-peptide (fasting, 2- and 5-h AUC) vs controls 
(Table  3). Obese patients with PCOS had significantly 
higher levels of insulin (fasting, 2- and 5-h AUC), C-pep-
tide (fasting, 2- and 5-h AUC) and HOMA-IR compared to 
lean patients (Table 4).
Discussion
To our knowledge, this is the first long-term randomized 
controlled clinical trial examining the effect of OCP and/or 
metformin treatment on GLP-1 secretion and risk of RH in 
PCOS. Fasting GLP-1 levels and the risk of RH increased in 
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Figure 2
Insulin and C-peptide levels before and after intervention.
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patients treated with metformin + OCP, whereas changes 
in AUC GLP-1 levels were comparable between the medical 
intervention groups despite significant changes in insulin 
sensitivity, body weight and testosterone levels. Increased 
risk of RH after medical intervention was associated with 
increased insulin levels during 5-h OGTT and was not 
predicted by AUC GLP-1 or BMI.
Few previous studies evaluated GLP-1 secretion during 
medical intervention in women with PCOS. In agreement 
with our study, a recent uncontrolled study reported 
unchanged GLP-1 levels during a standardized meal test 
following 3  months treatment with a 4th generation 
OCP (30 µg ethinyl estradiol/3 mg drospirenone) in 14 
lean patients with PCOS (4). Limited data are available 
on possible interactions between sex hormones and 
GLP-1. Treatment with GLP-1 increased LH secretion 
and induced puberty in female rats (17, 26). Increased 
LH in PCOS (27) could therefore be associated with 
higher GLP-1 levels. We found no association between 
testosterone and GLP-1 levels and GLP-1 levels were 
Table 2 Median changes in clinical and biochemical variables during medical intervention.
 Metformin (n = 19) OCP (n = 23) Metformin + OCP (n = 23)
Weight (kg)** −3.0 (−10.3; 0.6)¤§ 1.2 (−0.8; 3.0) −1.9 (−4.9; 0.1)¤
BMI (kg/m2)** −1.0 (−3.7; 0.2)¤§ 0.4 (−0.4; 1.2) −0.8 (−1.8; 0.03)¤
T-testosterone (nmol/L) −0.35 (−0.97; −0.06) −0.36 (−1.17; −0.04) −0.42 (−1.19; 0.01)
SHBG (nmol/L)** 9 (−2.19)¤¤§§ 138 (89; 162) 106 (59; 175)
FTI** −0.007¤§ (−0.019; 0.0036) −0.023 (−0.034; −0.008) −0.019 (−0.029; −0.014)
Fasting    
 GLP-1 (mmol/L)* 2.5 (0.3; 3.8) 1.3 (−1.0; 2.4) 3.0 (1.4; 4.6)¤
 Insulin (pmol/L)* 2 (−22; 16) 9 (−6; 46) −8 (−18; 6)¤
 C-peptide (pmol/L)* −86 (−237; 78)¤§ 95 (−73; 247) −97 (−289; 43)¤
 HOMA (mmol/L nmol/L) −0.2 (−5.5; 4.1) 1.7 (−1.1; 10.4) −0.6 (−5.1; 1.8)
OGTT    
 2 h AUC GLP-1 (102 mmol/L × h) 0.4 (−2.9; 3.4) −2.6 (−1.7; 10.9) 1.7 (−3.1; 8.9)
 5 h AUC GLP-1 (102 mmol/L × h) 3.2 (−4.1; 7.0) 0.3 (−0.4; 1.0) −0.2 (−1.8; 2.3)
 2 h AUC insulin (103 pmol/L × h) 0.5 (−13.0; 7.2) 6.5 (−5.3; 23.0) −0.3 (−9.0; 12.3)
 5 h AUC insulin (103 pmol/L × h) 1.0 (−20.2; 8.7) 13.1 (−4.4; 54.9) 3.6 (−11.5; 21.4)
 2 h AUC C-peptide (104 pmol/L × h) 1.6 (−42.3; 53.8) 2.6 (−3.2; 7.1) 0.8 (−1.5; 10.0)
 5 h AUC C-peptide (104 pmol/L × h)* 0.8 (−10.8; 5.4)¤ 8.7 (−3.1; 18.6) 4.4 (−1.6; 10.4)
Data presented as median (25; 75% quartiles). The median changes in BG (fasting, 2 h and 5 h AUC) were comparable in the three intervention groups 
(data not shown).
*P < 0.05, **P < 0.001, Kruskall–Wallis test between groups; ¤P < 0.05 vs OCP, Kruskall–Wallis test followed by Mann Whitney; §P < 0.05, §§P < 0.001 vs 
metformin + OCP, Kruskall–Wallis test followed by Mann Whitney.
FTI, free testosterone index; OCP, oral contraceptive treatment.
Table 3 Baseline clinical and biochemical data in patients and controls.
 PCOS (n = 90) Controls (n = 34)
Age (years) 28 (24–32) 26 (22–32)
Weight (kg) 73.7 (67.1; 85.3) 71.9 (67.6; 82.1)
BMI (kg/m2) 26.8 (23.3–30.8) 25.1 (22.6–27.4)
Fasting   
 GLP-1 (mmol/L) 9.0 (7.5; 10.9) 8.3 (7.0; 10.6)
 Insulin (pmol/L) 71 (50–95)* 55 (48–68)
 C-peptide (pmol/L) 707 (591–930)* 631 (561–727)
 HOMA (mmol/L nmol/L) 16.1 (11.7; 21.0) 14.2 (11.4; 16.5)
OGTT   
 2 h AUC GLP-1 (102 mmol/L*h) 18.0 (15.4; 22.7) 18.1 (16.1; 23.7)
 5 h AUC GLP-1 (102 mmol/L*h) 38.6 (31.7; 44.4) 37.0 (34.5; 46.6)
 2 h AUC BG (102 mmol/L*h) 8.9 (8.3; 9.8) 8.6 (8.3; 9.3)
 5 h AUC BG (102 mmol/L*h) 17.7 (16.5; 19.1) 18.5 (17.6; 19.0)
 2 h AUC insulin (103 pmol/L*h) 41.3 (30.7; 66.0)* 34.1 (22.9; 51.2)
 5 h AUC insulin (103 pmol/L*h) 60.8 (44.7; 89.9)* 48.3 (33.3; 70.6)
 2 h AUC C-peptide (104 pmol/L*h) 27.2 (22.7; 34.5)* 25.1 (20.4; 27.3)
 5 h AUC C-peptide (104 pmol/L*h) 50.4 (39.7; 63.2)** 42.6 (37.9; 47.2)
Data presented as median (25; 75 quartiles).
*P < 0.05, **P < 0.001 vs controls.
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unchanged despite normalized testosterone levels during 
treatment with OCP, which did not support an association 
between testosterone and GLP-1 secretion. In support of 
this hypothesis, total testosterone levels were unchanged 
during treatment with GLP-1 despite significant weight 
loss in patients with PCOS (28, 29).
We found that metformin treatment was associated 
with unchanged GLP-1 secretion, whereas insulin levels 
decreased during 5-h OGTT and the median weight loss 
was 3.0 kg (15). In contrast, Svendsen  et  al. reported 
increased GLP-1 secretion during 2-h OGTT after 8-month 
treatment with metformin in 22 lean and obese women 
with PCOS (6). Measures of insulin resistance were 
unchanged and no reduction in BMI was reported (6). 
In vitro and in vivo studies in patients with type 2 diabetes 
and obese non-diabetic subjects, supported that treatment 
with metformin could increase GLP-1 secretion directly by 
stimulating the GLP-1 producing cells and by decreasing 
soluble dipeptidyl peptidase-4 activity and thereby inhibit 
GLP-1 degradation (30, 31). We did therefore expect 
increased GLP-1 levels during metformin treatment. The 
median changes in fasting, 2-h and 5-h AUC GLP-1 levels 
during metformin treatment were positive, but the present 
long-term study design did not allow the inclusion of a 
placebo group. It is possible that metformin treatment 
could have short-term effects on GLP-1 secretion that 
does not persist during long-term treatment, but more 
studies are needed to test this hypothesis.
We tested the hypothesis that medical treatment in 
PCOS could change the risk of RH and that the risk of RH 
could be mediated by changes in GLP-1 and/or insulin 
secretion. The prevalence of RH increased in women 
treated with metformin + OCP, but OCP treatment and 
metformin treatment alone did not affect the risk of RH. 
Women with RH after study intervention had higher 
insulin secretion, whereas glucose stimulated GLP-1 
secretion and BMI was comparable in patients with and 
without RH. Increased risk of RH was seen in both lean and 
obese individuals. These findings supported that increased 
insulin secretion were the primary mediator of increased 
risk of RH. The power of the present study did not allow 
us to test the possibility that the mechanism for RH could 
differ between lean and obese subgroups of patients (9). 
We are not aware of previous studies that investigated the 
effect of treatment with metformin and/or OCP on the 
risk of RH in PCOS. The present study did not support our 
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GLP-1 levels in obese and lean patients with PCOS.
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hypothesis that weight gain during treatment with OCP 
was associated with increased risk of RH (32). However, 
insulin resistance was deteriorated during treatment 
with OCP as fasting and glucose-stimulated insulin levels 
increased. It is possible that the effects of OCP treatment 
on insulin and C-peptide levels were too modest to affect 
the risk of RH. In meta-analyses, treatment with OCP was 
associated with unchanged fasting insulin in PCOS (16), 
but fasting insulin is only a rough measure of insulin 
resistance (33) and different generation OCPs could have 
divergent effects on metabolic risk factors (34). Increased 
ghrelin levels during OCP treatment could be a marker of 
increased appetite, but previous data on ghrelin secretion 
during treatment with OCP in patients with PCOS were 
conflicting (35, 36). More data are therefore needed 
on the possible effects of different generation OCPs on 
metabolic risk including RH, appetite regulation and 
insulin resistance in PCOS.
We found that GLP-1 secretion was comparable 
in patients and controls both at fasting and during 5-h 
OGTT and GLP-1 levels were also comparable in obese 
and lean subgroups of patients and weight-matched 
controls. Results from recent studies on GLP-1 secretion 
in PCOS were conflicting. The majority of studies found 
no significant differences in GLP-1 levels between patients 
with PCOS and weight-matched controls (5, 6, 37), 
whereas lower GLP-1 levels in lean patients with PCOS 
vs weight-matched controls were reported in two studies 
(4, 38). Our findings are in agreement with the study by 
Svendsen  et  al. in 40 patients with PCOS (6), reporting 
comparable GLP-1 levels between patients with PCOS and 
controls overall and in lean and obese subgroups during 
2-h OGTT, whereas less than 25 patients were included in 
the remaining studies (4, 5, 37, 38). Furthermore, we used 
up-to-date methods for the measurement of GLP-1 (22) 
in contrast to previous studies (4, 5, 37, 38). Comparable 
measures of insulin resistance between patients and 
controls (4, 5, 6, 38) could have affected study outcomes 
in previous studies. Our findings of significantly higher 
measures of insulin resistance in PCOS vs controls further 
supported that BMI is the most important predictor 
of GLP-1 secretion in PCOS and that PCOS itself is not 
associated with changed GLP-1 secretion.
The strength of the present study was the randomized 
controlled design. A recent publication of similar sample 
size reported significant changes in GLP-1 secretion 
during metformin treatment (6). Furthermore, up-to-date 
methods were applied for the measurement of GLP-1 (22). 
This supported that the present study had power to detect 
changes in GLP-1 secretion during medical treatment. A 
study limitation was the inclusion of relatively lean women 
and that the long intervention period did not allow for 
the inclusion of a placebo group. Normal-weight patients 
had high drop-out rates especially in the two treatment 
arms including metformin, which could lead to type 1 
error, thus lack of power. P values were, however, close 
to one, which support our conclusions. The pathogenesis 
of insulin resistance in PCOS is multifactorial and insulin 
resistance is difficult to assess by mathematical indices 
(39). Furthermore, there are intra-individual variations 
in glucose levels, which could lead to misclassification of 
RH (40). Our findings regarding risk of RH during medical 
treatment in PCOS therefore need to be reproduced in 
future studies.
In conclusion, the present study supported that GLP-1 
levels were unchanged during medical intervention with 
metformin and/or OCP and increased risk of RH could be 
associated with increased insulin levels during medical 
intervention with metformin + OCP. GLP-1 secretion was 
predicted by BMI and not by PCOS-status.
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